Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic agent for motor neuron disease

a technology for motor neuron disease and therapeutic agents, applied in the field of motor neuron disease therapy and/or preventive agents, can solve the problems of no therapeutic agents effective for als, no neuronal cell death inhibitors, and atrophy of voluntary muscles, and achieve the effects of preventing neuronal cell death, and preventing als ons

Inactive Publication Date: 2009-03-19
NOEVIR CO LTD +2
View PDF5 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is about a newly identified peptide called "ADNF" that can protect motor neurons from cell death and improve motor function in mice with ALS. The invention provides a therapeutic and preventive agent for motor neuron disease that contains this peptide as an active ingredient. The peptide can be administered as a pharmaceutical or in a fusion peptide with other molecules for purification and detection. The invention also includes a method for producing the peptide and a use of the peptide for treating motor neuron disease.

Problems solved by technology

ALS causes muscular atrophy and muscular weakness in voluntary muscles in the whole body except for extraocular muscle, and eventually respiratory failure.
Thus, there are no therapeutic agents effective for ALS under present circumstances.
This unique but unfavorable property of ADNF have prevented it from being developed as an anti-Alzheimer's disease (AD) drug.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic agent for motor neuron disease
  • Therapeutic agent for motor neuron disease
  • Therapeutic agent for motor neuron disease

Examples

Experimental program
Comparison scheme
Effect test

example 1

Inhibition of SOD1 Mutant Gene-Induced Neuronal Cell Death by ADNF

(1) Test Materials

[0072]Wild-type SOD1 cDNA (SEQ ID NO: 4) and SOD1 mutant (A4T-SOD1, G85R-SOD1, and G93R-SOD1) cDNAs were kindly provided by Dr. Shoji Tsuji (Faculty of Medicine, the University of Tokyo). Kinase-inactive CaMKII and CaMKIV cDNAs were kindly provided by Dr. Howard Schulman, Stanford University, US. ADNF (SALLRSIPA: SEQ ID NO: 1) and ADNF8 (ALLRSIPA: SEQ ID NO: 2) were synthesized (Glazner G W, et al., 1999, J Neurochem 73: 2341-2347). IPAL peptide (IPALDSLKPANEDQKIGIEI: SEQ ID NO: 3, Zamostiano R, et al., 1999, Neurosci Lett 264: 9-12) was purchased from the Peptide Institute (Osaka, Japan). An anti-SOD1 antibody was purchased from MBL (Nagoya, Japan). PD98059, SB20380, AG490, KN93, KN92, and HA1004 were purchased from Calbiochem-Novabiochem (San Diego, USA).

[0073]F11 cell, the hybrid cell of rat embryonic day 13 (E13) primary cultured neuronal cell with mouse neuroblastoma NTG18 cell, was cultured in ...

example 2

Dose-Dependent Inhibitory Effect of ADNF on Neuronal Cell Death

[0082]F11 or NSC34 cells were used to confirm the dose-dependent effect of ADNF on neuronal cell death induced by transformation with SOD1 mutant genes (A4T-SOD1, G85R-SOD1, and G93R-SOD1).

[0083]F11 or NSC34 cells were transformed with pEF-BOS, A4T-SOD1, G85R-SOD1, or G93R-SOD1 cDNA in the presence of increasing concentrations (10 aM, 1 fM, 100 fM, 10 pM, 1 nM, and 100 nM) of ADNF. After 72 hours, cell mortality was measured by Trypan blue exclusion assay.

[0084]Although 10 aM ADNF hardly exhibited cell death inhibition, 100 fM ADNF completely decreased cell mortalities induced by these three types of SOD1 mutant genes to the level of the control (FIG. 2A). In this regard, the complete protective action of ADNF on cell death caused by the SOD1 mutant genes was observed at the concentrations equal to or above 10 nM. These results demonstrated the dose-dependent inhibitory activity of ADNF against neuronal cell death caused...

example 3

Analysis on Neuroprotective Action of ADNF

[0089]Intracellular signaling by ADNF was examined. F11 cells were transformed with pEF-BOS or SOD1 mutant (A4T-SOD1, G85R-SOD1, or G93R-SOD1) cDNA and reacted with 10 nM wortmannin (PI3 kinase inhibitor), 100 μM genistein (tyrosine kinase inhibitor), 50 μM PD98059 (MEK inhibitor), 20 μM SB203580 (p38 MAPK inhibitor), 1 μM AG490 (JAK kinase inhibitor), 5 μM KN93 (calcium / calmodulin-dependent kinase inhibitor), or 10 μM HA1004 (protein kinase A inhibitor) in the presence or absence of 100 nM ADNF. After 72 hours of the transformation, cell mortality was measured by Trypan blue exclusion assay.

[0090]The results obtained using A4T-SOD1, G85R-SOD1, and G93R-SOD1 are respectively shown in FIGS. 3A to 3C.

[0091]The neuroprotective effect of ADNF was not affected by wortmannin (W), PD98059 (PD), SB203580 (SB), AG490 (AG), and HA1004 (HA), but it was inhibited by genistein (G) and KN93 (KN) (FIGS. 3A to 3C). This suggests that ADNF exerts its neuropr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
humidityaaaaaaaaaa
concentrationsaaaaaaaaaa
hydrophobicaaaaaaaaaa
Login to View More

Abstract

An object of the present invention is to provide an agent effective for the treatment and / or prevention of motor neuron disease such as amyotrophic lateral sclerosis (ALS). The present invention provides a therapeutic and / or preventive agent for motor neuron disease comprising the following oligopeptide shown in any of (a) to (c) or a pharmaceutically acceptable salt thereof as an active ingredient: (a) an oligopeptide consisting of the amino acid sequence represented by Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO: 1); (b) an oligopeptide consisting of an amino acid sequence having a deletion, substitution, insertion, or addition of one or several amino acids in Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO: 1), and having an activity that inhibits neuronal cell death caused by a mutant superoxide dismutase-1 gene; and (c) a modified oligopeptide from the oligopeptide (a) or (b).

Description

TECHNICAL FIELD[0001]The present invention relates to a therapeutic and / or preventive agent for motor neuron disease, particularly amyotrophic lateral sclerosis (ALS).BACKGROUND ART[0002]Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that typically affects people of middle or advanced ages and selectively attacks motor nerves in the cerebrum, brain stem, and spinal cord (Cleveland D W and Rothstein J D, 2001, Nat Rev Neurosci 2: 806-819; and Hand C K and Rouleau G A, 2002, Muscle Nerve 25: 135-159). ALS causes muscular atrophy and muscular weakness in voluntary muscles in the whole body except for extraocular muscle, and eventually respiratory failure. Most patients die in 3 to 5 years from the onset.[0003]Riluzole is the sole drug previously approved for ALS in US and Japan. Riluzole was originally developed as an anticonvulsant inhibiting glutamate release and has been reported in several clinical trials to exhibit only slight efficacy for the survival of ALS p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/08A61P25/00A61K31/7088C07K19/00C07H21/04C12N15/63C12N1/21C12N1/19C12N5/10A61K38/00A61K38/16A61P25/02A61P25/28C07K7/06C07K14/47C12N1/15C12N15/09C12N15/12C12P21/02
CPCC07K14/47A61K38/16A61P21/04A61P25/00A61P25/02A61P25/28
Inventor AISO, SADAKAZUMATSUOKA, MASAAKICHIBA, TOMOHIROKITA, YOSHIKOTERASHITA, KENZO
Owner NOEVIR CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com